Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist. It mimics the gut incretin hormone GLP-1: slowing gastric emptying, acting on appetite centers in the hypothalamus to reduce hunger and food intake, and enhancing glucose-dependent insulin secretion. The appetite effect is the one that drives the weight loss — people simply eat less and feel full sooner. Structural modifications (a fatty-acid chain that binds albumin) give it a long enough half-life for once-weekly injection, and an oral formulation (Rybelsus) exists for the diabetes indication.

The evidence base here is genuinely strong and it is human RCT, not extrapolation. In STEP 1 (Wilding et al., 2021, NEJM), adults with overweight or obesity but without diabetes lost a mean of about 14.9% of body weight on 2.4 mg weekly over 68 weeks, versus roughly 2.4% on placebo. STEP 2 (Davies et al., 2021, Lancet) showed meaningful weight loss in people who also had type 2 diabetes, where weight reduction is typically harder to achieve. The SUSTAIN program established the glycemic and earlier cardiovascular data in diabetes. Then SELECT (Lincoff et al., 2023, NEJM) moved it past weight: in people with obesity and established cardiovascular disease but no diabetes, semaglutide cut the rate of major adverse cardiovascular events versus placebo. That outcome trial is what separates semaglutide from almost everything else discussed on this site — it has hard endpoint data, not just surrogate markers.

• Mean ~14.9% body-weight reduction in adults without diabetes (STEP 1, 68 weeks)
• Clinically meaningful weight loss in people with type 2 diabetes (STEP 2)
• Reduction in major adverse cardiovascular events in obesity with established CVD (SELECT)
• Robust HbA1c lowering across the SUSTAIN diabetes program

• Boxed warning: in rodents, GLP-1 agonists caused thyroid C-cell tumors; contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Human relevance is unestablished but the contraindication stands
• GI effects are very common: nausea, vomiting, diarrhea, constipation — usually dose-dependent and worst during dose escalation
• Reports of acute pancreatitis; discontinue if suspected
• Gallbladder events (cholelithiasis) occur, partly tied to rapid weight loss
• Prescription drug, not a supplement — use belongs under a licensed clinician; grey-market "research" sourcing is unsafe and outside the legal channel
• Weight regain is common after stopping unless lifestyle change is maintained

FDA-approved. Approved by the FDA for one or more human indications.

Goals studied: Fat loss, Body composition, Visceral fat reduction

What is the difference between Ozempic, Wegovy, and Rybelsus?

All three are semaglutide. Ozempic is the injectable approved for type 2 diabetes, Wegovy is the higher-dose injectable approved for chronic weight management, and Rybelsus is the oral tablet for type 2 diabetes. The molecule is the same; the brand, dose, and approved indication differ.

Does semaglutide do more than help with weight?

Yes — the SELECT trial showed it lowers the rate of heart attack, stroke, and cardiovascular death in people with obesity and existing heart disease. That hard-outcome data is unusual and is a major reason it is taken seriously beyond weight loss.

Is it safe to buy semaglutide from a research-peptide vendor?

No. Semaglutide is a prescription drug. Buying it from grey-market "research" suppliers means no quality control, no dose accuracy, no medical oversight of the thyroid and pancreatitis risks, and no legal standing. Legitimate access is through a licensed prescriber or telehealth clinic.

1. [1]
   Once-Weekly Semaglutide in Adults with Overweight or Obesity

   Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF · The New England Journal of Medicine · 2021 · PMID 33567185 · model: human

   STEP 1 phase 3 RCT in adults with overweight or obesity without diabetes, showing a mean ~14.9% body-weight reduction on semaglutide 2.4 mg weekly over 68 weeks versus placebo.

2. [2]
   Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

   Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I · Lancet · 2021 · PMID 33667417 · model: human

   STEP 2 phase 3 RCT showing semaglutide 2.4 mg produced significant weight loss in adults who had both overweight/obesity and type 2 diabetes.

3. [3]
   Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

   Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH · The New England Journal of Medicine · 2023 · PMID 37952131 · model: human

   SELECT outcome trial showing semaglutide reduced major adverse cardiovascular events versus placebo in people with obesity and established cardiovascular disease but without diabetes.